

Myriad Morcells™

Morcellized Bioscaffold

Myriad Morcells™ is a **conformable ECM graft** derived from **100% ARO A ECM**.

Myriad Morcells can help facilitate rapid granulation tissue formation and volumetric tissue infill.

ARO A ECM is more than just collagen

ARO A ECM is extracellular matrix (ECM) technology, that supplements patient's healing with important ECM proteins including growth factors, cytokines and anti-inflammatory proteins, known to help facilitate healing.^{1,2}



Myriad Morcells contains collagen and many ECM proteins that are important in healing³

| Product | Type of technology | Collagen type I | Collagen type II | Collagen type III | Collagen type IV | Fibronectin | Elastin | Hyaluronic acid | Growth factors and cytokines | Basement Membrane | Residual Vascular Channels |
|--------------------------------|---|--------------------|------------------|-------------------|------------------|------------------|------------------|-----------------|------------------------------|-------------------|----------------------------|
| Myriad Morcells | ECM ⁴ | Y ^{2,3} | Y ² | Y ^{2,3} | Y ^{2,3} | Y ^{2,3} | Y ^{2,3} | Y ³ | Y ^{2,3} | Y ^{2,3} | Y ⁴ |
| MicroMatrix® | ECM ⁶ | Y ^{6,7} | | Y ⁶ | Y ^{6,7} | Y ⁶ | Y ⁶ | | Y ⁶ | Y ⁶ | |
| OaSIS® | ECM ⁸ | Y ⁹ | Y ¹⁰ | Y ¹⁰ | Y ¹⁰ | Y ¹¹ | Y ¹² | Y ¹² | Y ¹²⁻¹⁴ | Y ⁹ | |
| CellerateRX® | Reconstituted collagen | Y ¹⁵ | | | | | | | | | |
| Integra® Flowable Wound Matrix | Reconstituted collagen and chondroitin sulphate | Y ^{16,17} | | | | | | | | | |
| NIVIS® | Reconstituted collagen | Y ¹⁸ | | Y ¹⁸ | | | | | | | |

Myriad Morcells™

Morcellized Bioscaffold

AROA ECM is proven and trusted globally



>187
PUBLICATIONS

AROA ECM is supported
by **>187 preclinical** and
clinical publications.



>6
MILLION


AROA ECM has been
used in **>6 million**
procedures globally.



AROA ECM™



Myriad products
are made from
AROA ECM™
regenerative
healing technology



Myriad Morcells enables regeneration of functional tissue

CASE 1:

A **49-year old male** with a full thickness abdominal trauma due to a motor vehicle accident who received several procedures including a laparotomy. A single application of **Myriad Morcells** (1000 mg) was used plus NPWT for 2 weeks. This wound was closed at week 6.

Pre-operative Assessment



Morcells application



Week 2



Week 6



Results may vary.

CASE 2:

A **36-year old male** with a full thickness wound following a facial trauma with parotid fistula. A single application of **Myriad Morcells** (500 mg) was used. This wound was 90% epithelialized at week 4.

Day 0



Day 0



Day 10



Week 6




Results may vary.

Myriad Morcells™

Morcellized Bioscaffold

Myriad Morcells comes in a range of pack sizes

| Myriad Morcells™ | |
|------------------|--------------|
| Stock no. | Product Size |
| PW01NA0200 | 200 mg |
| PW01NA0500 | 500 mg |
| PW01NA1000 | 1000 mg |



Myriad Morcells Fine - now available in a finer particulate

| Myriad Morcells Fine™ | |
|-----------------------|--------------|
| Stock no. | Product Size |
| PW02NA0200 | 200 mg |
| PW02NA0500 | 500 mg |
| PW02NA1000 | 1000 mg |



For more information, visit www.aroa.com

1. Badyalak, S.F., The extracellular matrix as a biologic scaffold material. *Biomaterials*, 2007, 28(25): p. 3587-93. 2. Dempsey, S.G., et al., Functional Insights from the Proteomic Inventory of Ovine Forestomach Matrix. *J Proteome Res*, 2019, 18(4): p. 1657-1668. 3. Lun, S., et al., A functional extracellular matrix biomaterial derived from ovine forestomach. *Biomaterials*, 2010, 31(16): p. 4517-29. 4. Smith, M.J., et al., Further structural characterization of ovine forestomach matrix and multi-layered extracellular matrix composites for soft tissue repair. *J Biomater Appl*, 2021, 36(6): p. 996-1010. 5. Gilbert, T.W., et al., Production and characterization of ECM powder: implications for tissue engineering applications. *Biomaterials*, 2005, 26(12): p. 1431-5. 6. Sadler, K., et al., Proteomic composition and immunomodulatory properties of urinary bladder matrix scaffolds in homeostasis and injury. *Semin Immunol*, 2017, 29: p. 14-23. 7. Bolland, F., et al., Development and characterisation of a full-thickness acellular porcine bladder matrix for tissue engineering. *Biomaterials*, 2007, 28(6): p. 1061-70. 8. Smith and Nephew website: <https://smith-nephew.com/en-us/health-care-professionals/products/advanced-wound-management/basis-us-only> (accessed 2nd May 2023). 9. Ji, Y., et al., Diverse preparation methods for small intestinal submucosa (SIS): Decellularization, components, and structure. *J Biomed Mater Res A*, 2019, 107(3): p. 689-697. 10. Shi, L. and V. Ronfard, Biochemical and biomechanical characterization of porcine small intestinal submucosa (SIS): a mini review. *Int J Burns Trauma*, 2013, 3(4): p. 173-9. 11. Lu, X., L. Han, and G.S. Kassab, Pulmonary Visceral Pleura Biomaterial: Elastin- and Collagen-Based Extracellular Matrix. *Frontiers in Bioengineering and Biotechnology*, 2022. 12. Hodde, J., et al., Glycosaminoglycan content of small intestinal submucosa: a bioscaffold for tissue repair. *Tissue Eng*, 1996, 2(3): p. 209-17. 13. Hodde, J. and M. Hiles, Bioactive FGF-2 in sterilized extracellular matrix. *Wounds*, 2001, 13(4): p. 195-201. 14. Hodde, J.P., et al., Vascular endothelial growth factor in porcine-derived extracellular matrix. *Endothelium*, 2001, 8(1): p. 11-24. 15. Stafyla, V., et al., Effect of collagen powder on lymphorrhea after modified radical mastectomy. A randomized controlled trial. *Eur J Gynaecol Oncol*, 2011, 32(2): p. 185-7. 16. Hodgkinson, T. and A. Bayat, Ex vivo evaluation of acellular and cellular collagen-glycosaminoglycan flowable matrices. *Biomed Mater*, 2015, 10(4): p. 041001. 17. Yannas, I.V., Tissue regeneration by use of collagen-glycosaminoglycan copolymers. *Clin Mater*, 1992, 9(3-4): p. 179-87. 18. Tela Bio website: <https://www.telabio.com/nivis.html> (accessed 3rd April 2023). 19. Data on file.

MicroMatrix® and Integra® Flowable Wound Matrix are registered trademarks of Integra LifeSciences. OaSIS® Micro is a registered trademark of Cook Biotech. CellerateRX® is a registered trademark of Sanara MedTech. NIVIS® is a registered trademark of Tela Bio.

RX Only. Prior to use, be sure to read the entire Instructions For Use package insert supplied with the product. Product information contained herein is for US customers.
Consult your local sales representative for country specific information.

To order Myriad Morcells™ or for more information, please call 1-877-627-6224 or email customerservice@aroa.com



ARO A™, Myriad Morcells™, Myriad Morcells Fine™ and ARO A ECM™ are trademarks of Aroa Biosurgery Limited.

MKT.1914.02 | ©August 2023